RIGL Rigel Pharmaceuticals, Inc. featured news, full reports, and detailed charts
Rigel Pharmaceuticals, Inc. (RIGL) Wrap Up:
Rigel Pharmaceuticals, Inc. was incorporated in Delaware in June 1996, and is based in South San Francisco. Rigel is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer and viral diseases. Our goal is to file one new investigative new drug, or IND, application in a significant indication each year. We have achieved this goal each year beginning in 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Our productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have internal product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis and thrombocytopenia, and cancer, as well as partnered product development programs relating to asthma and cancer. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f07%2f0001047469-08-002350.html#FIS_BUSINESS"www.rigel.com
181 Employees
Founded in 1996
Rigel Pharmaceuticals, Inc. (RIGL:NASDAQ)
LAST $7.78 USD
CHANGE TODAY 0.00 0.00%
VOLUME 332.9K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Rigel Pharmaceuticals, Inc. (RIGL)
|
OPEN
$7.70
|
PREVIOUS CLOSE
$7.78
|
|
|
DAY HIGH
$7.86
|
DAY LOW
$7.64
|
|
|
52 WEEK HIGH
07/21/09 - $14.75
|
52 WEEK LOW
03/6/09 - $4.19
|
|
|
MARKET CAP
403.2M
|
AVERAGE VOLUME 3 mo
634.5K
|
|
|
DILUTED EPS TTM
$-3.24
|
SHARES OUTSTANDING
51.8M
|
|
|
RIGL Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Marcial: Pharma Firms May Vie for Vertex
09/28/2009 9:54 AM ET
Stocks End Modestly Lower
09/17/2009 4:45 PM ET
RIGL Top Compensated Officers
Mr. James M. Gower
Chairman of the Board, Chief Executive Office...
Age: 60
Total Annual Compensation: $600.0K
Dr. Donald G. Payan M.D.
Co-Founder, President of Discovery & Research...
Age: 60
Total Annual Compensation: $483.0K
Mr. Ryan D. Maynard
Chief Financial Officer, Principal Accounting...
Age: 39
Total Annual Compensation: $300.0K
Mr. Raul R. Rodriguez
Chief Operating Officer and Executive Vice Pr...
Age: 48
Total Annual Compensation: $430.0K
Dr. Elliott B. Grossbard M.D.
Chief Medical Officer and Executive Vice Pres...
Age: 61
Total Annual Compensation: $450.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals Inc. Reports Unaudited Financial Results for the Third Quarter and Nine Months Ended September 30, 2009
11/3/2009
Rigel Pharmaceuticals Inc. reported unaudited financial results for the third quarter and nine months ended September 30, 2009. For the third quarter of 2009, the company reported a net loss of $26.7 million, or $0.70 per share, compared to a net loss of $37.7 million, or $1.03 per share, in the third quarter of 2008. Loss from operations was $26.7 million against $38.7 million a year ago. Loss before income taxes was $26.7 million against $37.7 million a year ago. For the nine months ended September 30, 2009, the company reported a net loss of $86.5 million, or $2.32 per share, compared to a net loss of $99.0 million in the first nine months of 2008, or $2.76 per share. Loss from operations was $86.9 million against $102.7 million a year ago. Loss before income taxes was $86.6 million against $98.98 million a year ago.
Rigel Pharmaceuticals, Inc. - Conference Presentation Call
10/26/2009
Rigel Pharmaceuticals, Inc. - Conference Presentation Calls
Rigel Pharmaceuticals, Inc. - Conference Presentation Call
10/22/2009
Rigel Pharmaceuticals, Inc. - Conference Presentation Calls
RIGL Competitors
| Company | Last | Change |
| Arena Pharmaceuticals Inc | $3.51 USD | -0.03 |
| InterMune Inc | $10.79 USD | -0.09 |
| MVIR BTA B, Medivir AB | kr78.00 SEK | +0.50 |
| Pharmasset Inc | $19.66 USD | +0.06 |
| Evotec Aktiengesellschaft | $6.27 USD | -0.03 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | RIGL | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 3.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
RIGL |
||
|
RIGL transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Rigel Pharmaceuticals, Inc.
More news for RIGL
Rigel Announces Third Quarter 2009 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL - News) today reported financial results for the third quarter and nine months ended September 30, 2009. For the third quarter of 2009, Rigel reported a net loss of $26.7 million, or $0.70 per share, compared to a net loss of $37.7 million, or $1.03 per share, in the third quarter of 2008. Weighted average shares outstanding for the third quarters of 2009 and 2008 were 38.1 million and 36.6 million, respectively.Rigel reported total operating expenses of $26.7 million in the third quarter of 2009, compared to $38.7 million in the third quarter of 2008. The decrease in operating expenses was primarily due to the completion of two Phase 2b clinical trials (TASKi2 and TASKi3) in July, a decrease in stock-based compensation expense, and cost savings resulting from our restructuring implemented in the first quarter of 2009. Stock-based compensation expenses decreased from $6.0 million in the third quarter of 2008 to $3.5 million in the third quarter of 2009, primarily due to a higher valuation of options granted in the first quarter of 2008 and full expense recognition of the majority of those options by the end of 2008.For the nine months ended September 30, 2009, Rigel reported a net loss of $86.5 million, or $2.32 per share, compared to a net loss of $99.0 million in the first nine months of 2008, or $2.76 per share.As of September 30, 2009, Rigel had cash, cash equivalents and available for sale securities of $...Click here to read the whole Article (external link)
Rigel 3Q loss narrows on lower costs
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Rigel reports $26.7M loss in Q3
ONLINE: home | business news | small business | sales & marketing | real estate | events | community | careers | city guide | advertise | about us | rss PRINT: subscribe | renew | advertise | book of lists | business intelligence | ...Click here to read the whole Article (external link)
New Star Analyst Rankings for Rigel Pharmaceuticals, Inc.
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...Click here to read the whole Article (external link)
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Show all filings for RIGEL PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for RIGEL PHARMACEUTICALS INC 3-Nov-2009Results of Operations and Financial Condition, Financial Statements and Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All informatio...Click here to read the whole Article (external link)
Piper Jaffray Award Winning Analyst Says Health Care Reform Equity Valuation Fears Have Passed: Stock Picks For Q4 2009
67 WALL STREET, New York - November 10, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Small-Cap Specialty Pharma - Patent Expiration - Pending Health Care Reform - Cultivating And Expanding R&D Pipelines - Chinese Drug Manufacturers - Brisk M&A Activity - Indian Pharma VS. U.S. Pharma - Competition From Generics - FDA Approval Process - Clinical Research Outsourcing Market - Stem Cell-Based Technology - Cancer Radiation Therapy - Expansion Into Asian Markets - Traditional Chinese Medicine VS. Western Medicine In Chinese Pharma Companies include: Aeolus Pharmaceuticals (AOLS.OB); Nutra Pharma (NPHC.OB); Quick-Med Technologies (QMDT.OB); Abbott Labs (ABT); Alexza Pharmaceuticals (ALXA); AmexDrug Corporation (AXRX.OB); Aurobindo Pharma (AUROBINDOP.BO); BioClinica (BIOC); BioPharm Asia (BFAR.OB); Biocon (BIOCON.BO); Cephalon (CEPH); China Sky One Medical, Inc. (CSKI); Claris Lifesciences (CLARICH.BO); Cortex Pharmaceuticals (COR); Daiichi Sankyo (DSKYF.PK); Dr.Reddy's (RDY); Elan (Elan); Eli Lilly (LLY); Forest (FRX); GeoPharma (GORX); Glaxo (GSK); Glenmark (GLENMARK.BO); Johnson & Johnson (JNJ); Lupin (LUPINSL.BO); Mannatech (MTEX); Matrix Laboratories (ATRIXLAB.BO); Medical Nutrition (MDNU); Merck KGaA (MKGAY.PK); Mylan (MYL); N...Click here to read the whole Article (external link)
RIGEL PHARMACEUTICALS INC Financials
PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue - - - - Cost of Revenue - - - - Gross Profit - - - - Operating ExpensesResearch Development21,082 24,948 24,538 28,402 Selling General and Administrative5,573 5,050 4,603 5,608 Non Recurring - - 1,141 - Others - - - - Total Operating Expenses - - - - Operating Income or Loss(26,655)(29,998)(30,282)(34,010)Income from Continuing OperationsTotal Other Income/Expenses Net48 159 347 586 Earnings Before Interest And Taxes(26,607)(29,839)(29,935)(33,424)Interest Expense44 69 53 29 Income Before Tax(26,651)(29,908)(29,988)(33,453)Income Tax Expense - (27)(66)(89)Minority Interest - - - - Net Income From Continuing Ops(26,651)(29,881)(29,922)(33,364)Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes - - - ...Click here to read the whole Article (external link)
Would you like to leave a comment about Rigel Pharmaceuticals, Inc. RIGL
Find out what social network information about Rigel Pharmaceuticals, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Rigel Pharmaceuticals, Inc. there is more great information available at Realpennies.com